{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:56Z","timestamp":1786119536541,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/spc.0b013e32833bd913","type":"journal-article","created":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T03:38:26Z","timestamp":1277782706000},"page":"147-152","source":"Crossref","is-referenced-by-count":25,"title":["Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management"],"prefix":"10.1097","volume":"4","author":[{"given":"Howard S","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20211004","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"R2-6-20211004","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1523-5394.2001.96009.x","article-title":"The treatment of prostate cancer: an overview of current options","volume":"9","author":"Pirtskhalaishvili","year":"2001","journal-title":"Cancer Pract"},{"key":"R3-6-20211004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-4295(02)02397-X","article-title":"Side effects of androgen deprivation therapy: monitoring and minimizing toxicity","volume":"61","author":"Higano","year":"2003","journal-title":"Urology"},{"key":"R4-6-20211004","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"R5-6-20211004","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1517\/14656566.9.16.2829","article-title":"Management of the side effects of androgen deprivation therapy in men with prostate cancer","volume":"9","author":"Flaig","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R6-6-20211004","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3322\/canjclin.52.3.154","article-title":"The current state of hormonal therapy for prostate cancer","volume":"52","author":"Hellerstedt","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"R7-6-20211004","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocr Rev"},{"key":"R8-6-20211004","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","article-title":"Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition","volume":"22","author":"Smith","year":"2004","journal-title":"J Clin Oncol"},{"key":"R9-6-20211004","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0022-5347(17)32530-2","article-title":"Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma","volume":"152","author":"Karling","year":"1994","journal-title":"J Urol"},{"key":"R10-6-20211004","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1442-2042.2004.00896.x","article-title":"Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy","volume":"11","author":"Nishiyama","year":"2004","journal-title":"Int J Urol"},{"key":"R11-6-20211004","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2001.19.17.3750","article-title":"Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study","volume":"19","author":"Potosky","year":"2001","journal-title":"J Clin Oncol"},{"key":"R12-6-20211004","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"R13-6-20211004","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","article-title":"Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer","volume":"166","author":"Oefelein","year":"2001","journal-title":"J Urol"},{"key":"R14-6-20211004","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"key":"R15-6-20211004","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-6-20211004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R17-6-20211004","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"R18-6-20211004","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R19-6-20211004","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"R20-6-20211004","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"R21-6-20211004","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","article-title":"Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02","volume":"54","author":"Efstathiou","year":"2008","journal-title":"Eur Urol"},{"key":"R22-6-20211004","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/01.ju.0000142068.66876.53","article-title":"The relative impact and future burden of prostate cancer in the United States","volume":"172","author":"Chan","year":"2004","journal-title":"J Urol"},{"key":"R23-6-20211004","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/S0022-5347(05)67511-8","article-title":"Prostate specific antigen only progression of prostate cancer","volume":"163","author":"Moul","year":"2000","journal-title":"J Urol"},{"key":"R24-6-20211004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1464-410X.2008.07539.x","article-title":"Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer","volume":"102","author":"Galvao","year":"2008","journal-title":"BJU Int"},{"key":"R25-6-20211004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0090-4295(89)90106-4","article-title":"Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma","volume":"33","author":"Peeling","year":"1989","journal-title":"Urology"},{"key":"R26-6-20211004","first-page":"110","article-title":"Testosterone, body composition and aging","volume":"22","author":"Vermeulen","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"R27-6-20211004","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-6-20211004","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/cncr.23440","article-title":"Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome","volume":"112","author":"Smith","year":"2008","journal-title":"Cancer"},{"key":"R29-6-20211004","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/cncr.21381","article-title":"Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma","volume":"104","author":"Lee","year":"2005","journal-title":"Cancer"},{"key":"R31-6-20211004","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-6-20211004","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2003.09.534","article-title":"Resistance exercise in men receiving androgen deprivation therapy for prostate cancer","volume":"21","author":"Segal","year":"2003","journal-title":"J Clin Oncol"},{"key":"R33-6-20211004","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jama.295.11.1288","article-title":"Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis","volume":"295","author":"Ding","year":"2006","journal-title":"JAMA"},{"key":"R34-6-20211004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R35-6-20211004","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2007.08.035","article-title":"Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer","volume":"71","author":"Smith","year":"2008","journal-title":"Urology"},{"key":"R36-6-20211004","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"key":"R37-6-20211004","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"R38-6-20211004","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.13.5517","article-title":"Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol"},{"key":"R39-6-20211004","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"R40-6-20211004","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"D'Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"R41-6-20211004","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/archinte.164.13.1427","article-title":"Effectiveness of statin therapy in adults with coronary heart disease","volume":"164","author":"Wilt","year":"2004","journal-title":"Arch Intern Med"},{"key":"R42-6-20211004","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3322\/caac.20061","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.","volume":"60","author":"Levine","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"R43-6-20211004","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4065\/77.11.1207","article-title":"Pathophysiology and treatment of hot flashes","volume":"77","author":"Shanafelt","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"R44-6-20211004","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.4065\/79.10.1247","article-title":"Pilot evaluation of paroxetine for treating hot flashes in men","volume":"79","author":"Loprinzi","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"R45-6-20211004","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00005392-199907000-00024","article-title":"Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer","volume":"162","author":"Quella","year":"1999","journal-title":"J Urol"},{"key":"R46-6-20211004","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1743-6109.2008.01053.x","article-title":"The social context for psychological distress from iatrogenic gynecomastia with suggestions for its management","volume":"6","author":"Wassersug","year":"2009","journal-title":"J Sex Med"},{"key":"R47-6-20211004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0090-4295(02)02107-6","article-title":"Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7\/SFUO-3","volume":"61","author":"Widmark","year":"2003","journal-title":"Urology"},{"key":"R48-6-20211004","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/030089160409000409","article-title":"Gynecomastia due to hormone therapy for advanced prostate cancer: a report of ten surgically treated cases and a review of treatment options","volume":"90","author":"Prezioso","year":"2004","journal-title":"Tumori"},{"key":"R49-6-20211004","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0022-5347(01)63595-X","article-title":"Tamoxifen as treatment for gynecomastia and mastodynia resulting from hormonal deprivation","volume":"159","author":"Serels","year":"1998","journal-title":"J Urol"}],"container-title":["Current Opinion in Supportive & Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01263393-201009000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:23:12Z","timestamp":1786040592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01263393-201009000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e32833bd913","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}